OptimizeRx Corporation (OPRX)
NASDAQ: OPRX · Real-Time Price · USD
17.02
-0.31 (-1.79%)
Aug 14, 2025, 2:10 PM - Market open
OptimizeRx Revenue
OptimizeRx had revenue of $29.20M in the quarter ending June 30, 2025, with 55.19% growth. This brings the company's revenue in the last twelve months to $104.75M, up 25.89% year-over-year. In the year 2024, OptimizeRx had annual revenue of $92.13M with 28.81% growth.
Revenue (ttm)
$104.75M
Revenue Growth
+25.89%
P/S Ratio
3.05
Revenue / Employee
$812,000
Employees
129
Market Cap
315.98M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 92.13M | 20.61M | 28.81% |
Dec 31, 2023 | 71.52M | 9.07M | 14.53% |
Dec 31, 2022 | 62.45M | 1.16M | 1.89% |
Dec 31, 2021 | 61.29M | 17.98M | 41.51% |
Dec 31, 2020 | 43.31M | 18.72M | 76.08% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
OPRX News
- 5 days ago - OptimizeRx Corporation (OPRX) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 6 days ago - OptimizeRx Reports Second Quarter 2025 Financial Results and Updates Fiscal Year 2025 Guidance - GlobeNewsWire
- 26 days ago - OptimizeRx: Stock Could Rise As Profitability Is Achieved - Seeking Alpha
- 4 weeks ago - OptimizeRx Sets Second Quarter 2025 Conference Call for August 7, 2025, at 4:30 p.m. ET - GlobeNewsWire
- 7 weeks ago - OptimizeRx Corporation Appoints CEO Steve Silvestro to Board of Directors - GlobeNewsWire
- 2 months ago - Simulmedia and OptimizeRx Announce Partnership from the Cannes Lions - Business Wire
- 3 months ago - OptimizeRx to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 3 months ago - OptimizeRx Corporation (OPRX) Q1 2025 Earnings Call Transcript - Seeking Alpha